News Column

Research Conducted at Food and Drug Administration Has Provided New Information about Risk Management

May 16, 2014

By a News Reporter-Staff News Editor at Insurance Weekly News -- Data detailed on Risk Management have been presented. According to news originating from Rockville, Maryland, by VerticalNews correspondents, research stated, "The use of thimerosal preservative in childhood vaccines has been largely eliminated over the past decade in the United States because vaccines have been reformulated in single-dose vials that do not require preservative. An exception is the inactivated influenza vaccines, which are formulated in both multidose vials requiring preservative and preservative-free single-dose vials."

Our news journalists obtained a quote from the research from Food and Drug Administration, "As part of an ongoing evaluation by USFDA of the safety of biologics throughout their lifecycle, the infant body burden of mercury following scheduled exposures to thimerosal preservative in inactivated influenza vaccines in the United States was estimated and compared to the infant body burden of mercury following daily exposures to dietary methylmercury at the reference dose established by the USEPA. Body burdens were estimated using kinetic parameters derived from experiments conducted in infant monkeys that were exposed episodically to thimerosal or MeHg at identical doses. We found that the body burden of mercury (AUC) in infants (including low birth weight) over the first 4.5 years of life following yearly exposures to thimerosal was two orders of magnitude lower than that estimated for exposures to the lowest regulatory threshold for MeHg over the same time period. In addition, peak body burdens of mercury following episodic exposures to thimerosal in this worst-case analysis did not exceed the corresponding safe body burden of mercury from methylmercury at any time, even for low-birth-weight infants."

According to the news editors, the research concluded: "Our pharmacokinetic analysis supports the acknowledged safety of thimerosal when used as a preservative at current levels in certain multidose infant vaccines in the United States."

For more information on this research see: A Comparative Pharmacokinetic Estimate of Mercury in U.S. Infants Following Yearly Exposures to Inactivated Influenza Vaccines Containing Thimerosal. Risk Analysis, 2014;34(4):735-750. Risk Analysis can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell -; Risk Analysis -

The news correspondents report that additional information may be obtained from R.J. Mitkus, Food & Drug Administration, Off Biostat & Epidemiol, Center Biol Evaluat & Res, Rockville, MD 20852, United States. Additional authors for this research include D.B. King, M.O. Walderhaug and R.A. Forshee.

Keywords for this news article include: Maryland, Rockville, United States, Risk Management, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories on investments and markets, please see HispanicBusiness' Finance Channel

Source: Insurance Weekly News

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters